



**MAURIZIO SCARPA, MD PhD**

Department of Pediatrics  
University of Padova and Center for Rare Disorders  
Via Giustiniani 3, 35121 Padova, Italy  
Tel. +39-049-8213505 FAX +39-049-8213502  
Email: maurizio.scarpa@unipd.it

DATE AND PLACE OF BIRTH September 15, 1959, Venice, Italy.  
CITIZENSHIP Italian.  
LANGUAGES English.  
POSITION HELD 3-1991-present Assistant Professor, Head of the Lysosomal Unit, Head Molecular Biology Laboratory and Center for Rare Disorders Dept. of Pediatrics, University of Padova, Italy

**EDUCATION**

December 1980- November 1985: Working group on Cystic Fibrosis, Dept. of Pediatrics, University of Padova, Italy.

November 1985 M.D. Degree, University of Padova, Medical School , Padova, Italy.

December 1985- August 1987 Postdoctoral fellowship  
Prof. Gianni Cesareni's laboratory  
Dept. Gene Structure and Regulation  
European Molecular Biology Laboratory  
(E.M.B.L.) Heidelberg, Germany

September 1987- December 1987 Dept. of Pediatrics, University of Padova, Italy.

January 1988-June 1990 Postdoctoral Fellowship.  
Prof. Charles Thomas Caskey's laboratory.  
Institute for Molecular Genetics, Baylor College of Medicine, Houston,Texas, U.S.A.

July 1990-February 1993 Consultant in Molecular Biology  
Prof. GianFranco Bottazzo's Laboratory  
Department of Immunology  
The London Hospital Medical College, London, UK.

February 1991-Present Head of the Gene Transfer Laboratory and Lysosomal Clinical Unit,  
Dept. of Pediatrics and Centre for Rare Disorders  
University of Padova, Italy.

**CERTIFICATIONS**

November 1985 Medical Doctor Degree, University of Padova, Italy.  
December 1985 License for Medical Practice, Italian Ministry of Health  
July 1989 Diploma of Pediatrics, Department of Pediatrics,  
University of Padova, Italy.  
July 2004 PhD Degree, University of Padova, Medical School

## **AWARDS**

January 1986- August 1987	Junior travel postdoctoral fellowship, Department of Pediatrics University of Padova, Italy.
January 1988-June 1988	Research Associate, Howard Hughes Medical Institute, Institute for Molecular Genetics, Baylor College of Medicine, Houston, Texas, U.S.A.
July 1988-June 1990	Postdoctoral Fellowship, Cystic Fibrosis Foundation, Bethesda, Maryland, U.S.A.
July 1990-February 1992	Charles Fremes Award, Juvenil Diabetes Foundation, New York, New York. U.S.A.
March 1991	First International Prize "Carlo Baschirotto" on Rare Genetic Diseaseas.

## **MEMBERSHIPS**

1992-present	Founding Member of the European Society for Gene Therapy
1994-present	Member of the Scientific Committe, Italian Association for Mucopolisaccharidosis.
1994	Member of the Gene Therapy Committee Italian Minister for the EEC, Commission on Safety of Genetically Modified Microorganisms.
1999-present	Member of the European Study Group for Lysosomal Diseases (ESLGD)
2000-present	Member Society for the Study of the Inborn Errors of Metabolism (SSIEM)
2002-2007	Founding Member: Global Organization for Lysosomal Disease (G.O.L.D.)
2007-present	Founder of BRAINS FOR BRAIN European Task Force for the Research on Pediatric Neurodegenerative Disorders
2009-present	VicePresident BRAINS For BRAIN FOUNDATION
2010-present	Member of the European Science Foundation Pool of reviewers

## **TEACHING ACTIVITIES**

2002-	Present: Director PhD Programme on Molecular Genetics and Biochemistry, University of Padova, Italy
2004-present:	Professor of Applied Biology, School of Neurosurgery, University of Padova

2004-present: Professor of Biochemistry, School of Neuropsychiatry University of Padova

2004-Present: Professor of Molecular Biology School of Neuropsychiatry University of Padova.

2008-Present Vice-Dean for the International Affairs Office University of Padova Medical School

N.	PUBLICATIONS
1)	Antagonistic controls regulate copy number of the yeast 2 mu plasmid.. MURRAY, JA;SCARPA, M;ROSSI, N;CESARENI, G. EMBO J. 1988. ; 6:4205-12 IF: 13.999 <a href="#">IDPUBMED</a>
2)	Genetic and structural analysis of the ColE1 Rop (Rom) protein.. CASTAGNOLI, L;SCARPA, M;KOKKINIDIS, M;BANNER, DW;TSEKNOGLOU, D;CESARENI, G. EMBO J. 1989. ; 8:621-9 IF: 13.999 <a href="#">IDPUBMED</a>
3)	Determination of base specificity in 6,4,4'-trimethylangelicin photobinding to single-stranded DNA.. MIOLO, G;SCARPA, M;DALL'ACQUA, F;ZACCHELLO, F. J PHOTOCH PHOTOBIO B. 1989. ; 3:123-7 IF: 1.529 <a href="#">IDPUBMED</a>
4)	Gene therapy: a new approach for the treatment of genetic disorders.. COURNOYER, D;SCARPA, M;JONES, SN;MOORE, KA;BELMONT, JW;CASKEY, CT. Clinical Pharmacology and Therapeutics. 1990. ; 47:1-11 IF: 5.275 <a href="#">IDPUBMED</a>
5)	SCREENING FOR CYSTIC-FIBROSIS GENE-MUTATIONS BY MULTIPLEX DNA AMPLIFICATION. PICCI, L; ANGLANI, F; SCARPA, M; ZACCHELLO, F. HUM GENET. 1992. ; 88(5):552-556 IF: 3.422 <a href="#">Riferimento WoK</a>
6)	Screening for cystic fibrosis gene mutations by multiplex DNA amplification.. PICCI, L;ANGLANI, F;SCARPA, M;ZACCHELLO, F . HUM GENET. 1992. ; 88:552-6 IF: 3.422 <a href="#">IDPUBMED</a>
7)	Gene therapy.. COURNOYER, D;SCARPA, M;CASKEY, CT. Current Opinion in Biotechnology. 1992. ; 1:196-208 IF: 4.711 <a href="#">IDPUBMED</a>

8)	<p>Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector..  MOORE, KA;SCARPA, M;KOOYER, S;UTTER, A;CASKEY, CT;BELMONT, JW.  Human gene therapy. 1992. ; 2:307-15 IF: 6.796  <a href="#">IDPUBMED</a></p>
9)	<p>Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells..  COURNOYER, D;SCARPA, M;MITANI, K;MOORE, KA;MARKOWITZ, D;BANK, A;BELMONT, JW;CASKEY, CT.  Human gene therapy. 1992. ; 2:203-13 IF: 6.796  <a href="#">IDPUBMED</a></p>
10)	<p>GENE-TRANSFER IN REGENERATING MUSCLE.  VITADELLO, M; NOVELLI, A; PICARD, A; SCHIAFFINO, MV; SCARPA, M; SCHIAFFINO, S.  J CELL BIOCHEM. 1993. ; 0(0):252-252 IF: 2.775  <a href="#">Riferimento WoK</a></p>
11)	<p>GENE-TRANSFER IN REGENERATING MUSCLE.  VITADELLO, M; SCHIAFFINO, MV; PICARD, A; SCARPA, M; SCHIAFFINO, S.  Human gene therapy. 1994. ; 5(1):11-18 IF: 6.796  <a href="#">Riferimento WoK</a></p>
12)	<p>ANTIRETROVIRAL ACTIVITY OF FUROCOUMARINS PLUS UVA LIGHT DETECTED BY A REPLICATION-DEFECTIVE RETROVIRUS.  MIOLO, G; TOMANIN, R; DEROSI, A; DALLACQUA, F; ZACCHELLO, F; SCARPA, M.  J PHOTOCH PHOTOBIO B. 1994. ; 26(3):241-247 IF: 1.529  <a href="#">Riferimento WoK</a></p>
13)	<p>Gene transfer in regenerating muscle..  VITADELLO, M;SCHIAFFINO, MV;PICARD, A;SCARPA, M;SCHIAFFINO, S.  Human gene therapy. 1994. ; 5:11-8 IF: 6.796  <a href="#">IDPUBMED</a></p>
14)	<p>Antiretroviral activity of furocoumarins plus UVA light detected by a replication-defective retrovirus..  MIOLO, G;TOMANIN, R;DE, ROSSI, A;DALL'ACQUA, F;ZACCHELLO, F;SCARPA, M.  J PHOTOCH PHOTOBIO B. 1995. ; 26:241-7 IF: 1.529  <a href="#">IDPUBMED</a></p>
15)	<p>In vitro and in vivo gene transfer to pulmonary cells mediated by cationic liposomes.  Fortunati, E; Bout, A; Zanta, MA; Valerio, D; Scarpa, M.  BBA-GENE STRUCT EXPR. 1996. ; 1306(1):55-62 IF: 2.243  <a href="#">Riferimento WoK</a></p>
16)	<p>ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo.  Ferrari, S; Moro, E; Pettenazzo, A; Behr, JP; Zacchello, F; Scarpa, M.  GENE THER. 1997. ; 4(10):1100-1106 IF: 5.964  <a href="#">Riferimento WoK</a></p>
17)	<p>The bacteriophage T7 binary system activates transient transgene expression in zebrafish (Danio rerio) embryos.  Verri, T; Argenton, F; Tomanin, R; Scarpa, M; Storelli, C; Costa, R; Colombo, L; Bortolussi, M.  BIOCHEM BIOPH RES CO. 1997. ; 237(3):492-495 IF: 3.055</p>

	<a href="#">Riferimento WoK</a>
18)	Development and characterization of a binary gene expression system based on bacteriophage T7 components in adenovirus vectors. Tomanin, R; Bett, AJ; Picci, L; Scarpa, M; Graham, FL. GENE. 1997. ; 193(2):129-140 IF: 2.461 <a href="#">Riferimento WoK</a>
19)	In vitro correction of iduronate-2-sulfatase deficiency by adenovirus-mediated gene transfer. DiFrancesco, C; Cracco, C; Tomanin, R; Picci, L; Ventura, L; Zacchello, F; DiNatale, P; Anson, DS; Hopwood, JJ; Graham, FL; Scarpa, M. GENE THER. 1997. ; 4(5):442-448 IF: 5.964 <a href="#">Riferimento WoK</a>
20)	In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Rosolen, A; Frascella, E; di Francesco, C; Todesco, A; Petrone, M; Mehtali, M; Zacchello, F; Zanesco, L; Scarpa, M. GENE THER. 1998. ; 5(1):113-120 IF: 5.964 <a href="#">Riferimento WoK</a>
21)	ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo.. FERRARI, S;MORO, E;PETTENAZZO, A;BEHR, JP;ZACCHELLO, F;SCARPA, M. GENE THER. 1998. ; 4:1100-6 IF: 5.964 <a href="#">IDPUBMED</a>
22)	Polyethylenimine shows properties of interest for cystic fibrosis gene therapy. Ferrari, S; Pettenazzo, A; Garbati, N; Zacchello, F; Behr, JP; Scarpa, M. BBA-GENE STRUCT EXPR. 1999. ; 1447(2):219-225 IF: 2.243 <a href="#">Riferimento WoK</a>
23)	Recombinant adenoviral vector-LipofectAMINE complex for gene transduction into human T lymphocytes. Di Nicola, M; Milanesi, M; Magni, M; Bregni, M; Carlo-Stella, C; Longoni, P; Tomanin, R; Ravagnani, F; Scarpa, M; Jordan, C; Gianni, AM. Human gene therapy. 1999. ; 10(11):1875-1884 IF: 6.796 <a href="#">Riferimento WoK</a>
24)	Detection of five rare cystic fibrosis mutations peculiar to southern Italy: Implications in screening for the disease and phenotype characterization for patients with homozygote mutations. Castaldo, G; Fuccio, A; Cazeneuve, C; Picci, L; Salvatore, D; Raia, V; Scarpa, M; Goossens, M; Salvatore, F. CLIN CHEM. 1999. ; 45(7):957-962 IF: 4.261 <a href="#">Riferimento WoK</a>
25)	A noval nonsense mutation (Y849X) in the CFTR gene of a CF patient from southern Italy.. Castaldo, G;Fuccio, A;Cazeneuve, C;Picci, L;Salvatore, D;Scarpa, M;Goossens, M;Salvatore, F. . HUM MUTAT. 1999. ; 14:- IF: 3.666 <a href="#">IDPUBMED</a>
26)	Large-scale feasibility of gene transduction into human CD34(+) cell-derived dendritic cells by adenoviral/polycation complex. Di Nicola, M; Carlo-Stella, C; Milanesi, M; Magni, M; Longoni, P; Mortarini, R; Anichini, A;

	<p>Tomanin, R; Scarpa, M; Gianni, AM. BRIT J HAEMATOL. 2000. ; 111(1):344-350 IF: 3.068 <a href="#">Riferimento WoK</a></p>
27)	<p>Genetic testing - Part I - Introduction. Scarpa, M. Minerva Biotechnologica. 2000. ; 12(1):3-3 IF: 0.233 <a href="#">Riferimento WoK</a></p>
28)	<p>Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Ferrari, S; Kitson, C; Farley, R; Steel, R; Marriott, C; Parkins, DA; Scarpa, M; Wainwright, B; Evans, MJ; Colledge, WH; Geddes, DM; Alton, EFWF. GENE THER. 2001. ; 8(18):1380-1386 IF: 5.893 <a href="#">Riferimento WoK</a></p>
29)	<p>Update on enzyme replacement therapy in mucopolysaccharidosis type II. Muenzer, J; Scarpa, M. ACTA PAEDIATR. 2002. ; 91(0):81-81 IF: 1.26 <a href="#">Riferimento WoK</a></p>
30)	<p>Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome). Tomanin, R; Friso, A; Alba, S; Puicher, EP; Mennuni, C; La Monica, N; Hortelano, G; Zacchello, F; Scarpa, M. ACTA PAEDIATR. 2002. ; 91(0):100-104 IF: 1.26 <a href="#">Riferimento WoK</a></p>
31)	<p>Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro. Daniele, A; Tomanin, R; Villani, GRD; Zacchello, F; Scarpa, M; Di Natale, P. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2002. ; 1588(3):203-209 IF: 3.3 <a href="#">Riferimento WoK</a></p>
32)	<p>Electrogene transfer in Mucopolysaccharidosis type II mouse model induces high-level production of iduronate-2-sulfatase in the skeletal muscle. Tomanin, R; Friso, A; Alba, S; Puicher, EP; Gasparotto, N; Mennuni, C; La Monica, N; Muenzer, J; Zacchello, F; Scarpa, M. MOL THER. 2003. ; 7(5):1024 - IF: 6.125 <a href="#">Riferimento WoK</a></p>
33)	<p>Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome).. TOMANIN, R;FRISO, A;ALBA, S;PILLER, PUICHER, E;MENNUNI, C;LA, MONICA, N;HORTELANO, G;ZACCHELLO, F;SCARPA, M . ACTA PAEDIATR. 2003. ; 91:100-4 IF: 1.128 <a href="#">IDPUBMED</a></p>
34)	<p>Chimeric vectors. Scarpa, M. Current gene therapy. 2004. ; 4(4):- IF: 3.681 <a href="#">Riferimento WoK</a></p>
35)	<p>Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction.</p>

	<p>Tomanin, R; Scarpa, M. Current gene therapy. 2004. ; 4(4):357-372 IF: 3.681 <a href="#">Riferimento WoK</a></p>
36)	<p>Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. Friso, A; Tomanin, R; Alba, S; Gasparotto, N; Puicher, EP; Fusco, M; Hortelano, G; Muenzer, J; Marin, O; Zacchello, F; Scarpa, M. J GENE MED. 2005. ; 7(11):1482-1491 IF: 3.699 <a href="#">Riferimento WoK DOI</a></p>
37)	<p>Gender-sensitive association of CFTR gene mutations and 5T allele emerging from a large survey on infertility. Morea, A; Cameran, M; Rebuffi, AG; Marzenta, D; Marangon, O; Picci, L; Zacchello, F; Scarpa, M. MOL HUM REPROD. 2005. ; 11(8):607-614 IF: 3.191 <a href="#">Riferimento WoK DOI</a></p>
38)	<p>Update on enzyme replacement therapy (ERT) with recombinant human arylsulfatase B (rhASB) for MPS VI (Maroteaux-Lamy). Harmatz, P; Giugliani, R; Schwartz, I; Guffon, N; Miranda, CS; Teles, E; Wraith, JE; Beck, M; Scarpa, M; Yu, ZF; Wittes, J; Berger, K; Newman, M. PEDIATR RES. 2005. ; 58(2):169 - IF: 2.875 <a href="#">Riferimento WoK</a></p>
39)	<p>Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers. Castellani, C; Picci, L; Scarpa, M; Dehecchi, MC; Zanolla, L; Assael, BM; Zacchello, F. AM J MED GENET A. 2005. ; 135(2):142-144 IF: 1.913 <a href="#">Riferimento WoK DOI</a></p>
40)	<p>A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, MULTINATIONAL CLINICAL STUDY OF RECOMBINANT HUMAN N-ACETYL GALACTOSAMINE 4 SULFATASE (RHASB) IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS VI. Guffon, N.; Harmatz, P.; Giugliani, R.; Schwartz, I.; Miranda, C.; Teles, E.; Wraith, Ed; Beck, M.; Arash, L.; Scarpa, M.; Swiedler, S.. J INHERIT METAB DIS. 2005. ; 28(0):190-190 IF: 3.598 <a href="#">Riferimento WoK</a></p>
41)	<p>A 3-year-old child with abdominal pain and fever.. BONETTO, G;SCARPA, M;CARRARO, S;BARALDI, E. EUR RESPIR J. 2005. ; 26:974-7 IF: 3.947 <a href="#">IDPUBMED</a></p>
42)	<p>Enzyme replacement therapy for mucopolysaccharidosis VI: A Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. Harmatz, P; Giugliani, R; Schwarziz, I; Guffon, N; Teles, EL; Miranda, MCS; Wraith, JE; Beck, M; Arash, L; Scarpa, M; Yu, ZF; Wittes, J; Berger, KI; Newman, MS; Lowe, AM; Kakkis, E; Swiedler, SJ. J PEDIATR. 2006. ; 148(4):533-539 IF: 3.991 <a href="#">Riferimento WoK DOI</a></p>

43)	<p>Long term benefit and safety with recombinant human arylsulfatase, B (rhASB) ERT for MPS VI. Harmatz, P.; Giugliani, R.; Schwartz, I.; Guffon, N.; Sa Miranda, C.; Teles, E.; Wraith, J. E.; Beck, M.; Scarpa, M.; Yu, Z-F; Rhorer, J.; Swiedler, S. J.; Decker, C..</p> <p>J INHERIT METAB DIS. 2006. ; 29(0):29-29 IF: 3.598</p> <p><a href="#">Riferimento WoK</a></p>
44)	<p>Neurological examinations and clinical manifestations in MPS I as reported in the MPS I registry. Scarpa, M..</p> <p>J INHERIT METAB DIS. 2007. ; 30(0):97-97 IF:3.598</p> <p><a href="#">Riferimento WoK</a></p>
45)	<p>Phase 3 extension 96-week study data for naglazyme (galsulfase) enzyme replacement therapy (ERT) in MPS VI (Maroteaux-Lamy syndrome) patients. Harmatz, P.; Gingliani, R.; Schwartz, I; Guffon, N.; Sa, Miranda C.; Teles, E.; Wraith, J.; Beck, M.; Scarpa, M.; Yu, Z. F.; Rhorer, J.; Swiedler, S.; Turbeville, S.; Nicely, H.; White, J.; Decker, C..</p> <p>J INHERIT METAB DIS. 2007. ; 30(0):116-116 IF: 3.598</p> <p><a href="#">Riferimento WoK</a></p>
46)	<p>TG15 T5 allele in clinically discordant monozygotic twins with cystic fibrosis. Picci, Luigi; Cameran, Marilena; Scarpa, Maurizio; Pradal, Ugo; Melotti, Paola; Assael, Baroukh M.; Castellani, Carlo.</p> <p>AM J MED GENET A. 2007. ; 143(16):1936-1937 IF: 2.44</p> <p><a href="#">Riferimento WoK DOI</a></p>
47)	<p>Efficiency of stem cell infections of amniotic fluid by means of adenoviral carriers. Piccoli, M.; Grisafi, D.; Pozzobon, M.; Bollini, S.; Marangoni, P.; Carli, M.; Zanesco, L.; Scarpa, M.; De, Coppi P.; Tomanin, R..</p> <p>HAEMATOL-HEMATOL J. 2007. ; 92(6):45-45 IF: 5.516</p> <p><a href="#">Riferimento WoK</a></p>
48)	<p>Neurologic examinations and clinical manifestations in mucopolysaccharidosis I: MPS I registry data. Scarpa, M..</p> <p>Clinical Therapeutics. 2007. ; 29(0):S123-S123 IF: 3.261</p> <p><a href="#">Riferimento WoK</a></p>
49)	<p>High Transduction Efficiency of Human Amniotic Fluid Stem Cells Mediated by Adenovirus Vectors. Grisafi, Davide; Piccoli, Martina; Pozzobon, Michela; Ditadi, Andrea; Zaramella, Patrizia; Chiandetti, Lino; Zanon, Giovanni Franco; Atala, Anthony; Zacchello, Franco; Scarpa, Maurizio; De Coppi, Paolo; Tomanin, Rosella.</p> <p>Stem Cells and Development. 2008. ; 17(5):953-962 IF: 3.273</p> <p><a href="#">Riferimento WoK DOI</a></p>
50)	<p>Gene therapy of Hunter syndrome: Evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS). Friso, A.; Tomanin, R.; Zanetti, A.; Mennuni, C.; Calvaruso, F.; La Monica, N.; Marin, O.; Zacchello, F.; Scarpa, M..</p> <p>Biochimica et Biophysica Acta - Molecular Basis of Disease. 2008. ; 1782(10):574-580 IF: 4.579</p> <p><a href="#">Riferimento WoK DOI</a></p>



51)	<p>Molecular analysis of 82 mucopolysaccharidosis type I patients: Mutational spectrum in the European population and identification of 28 novel mutations. Bertola, F.; Parini, R.; Casati, G.; Tylki-Szymanska, A.; Okur, I.; Tuysuz, B.; Dalmau, J.; Gonzales, Meneses A.; Antuzzi, D.; Barone, R.; Dionisi, Vici C.; Donati, A.; Filocamo, M.; Gabrielli, O.; Parenti, G.; Scarpa, M.; Uziel, G.; Biondi, A.. J INHERIT METAB DIS. 2008. ; 31(0):426P - IF: 3.598 <a href="#">Riferimento WoK</a></p>
52)	<p>Morquio syndrome: Gene expression profiling and elastic fiber assembly in patients' fibroblasts. Caciotti, A.; Carraresi, L.; Filoni, C.; Parini, R.; Antuzzi, D.; Ricci, R.; Scarpa, M.; Procopio, E.; Dazzo, A.; Zammarchi, E.; Guerrini, R.; Donati, M. A.; Morrone, A.. J INHERIT METAB DIS. 2008. ; 31(0):447P - IF:3.598 <a href="#">Riferimento WoK</a></p>
53)	<p>Clinical phenotype of Italian patients with Hunter syndrome: Data from HOS - The Hunter Outcome Survey. Parini, R.; Melzi, M. L.; Rigoldi, M.; Sala, S.; Rampazzo, A.; Gabrielli, O.; DiRocco, M.; Feliciani, C.; Castorina, M.; Cicognani, A.; Scarpa, M.. J INHERIT METAB DIS. 2008. ; 31(0):456P - IF: 3.598 <a href="#">Riferimento WoK</a></p>
54)	<p>Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Harmatz, Paul; Giugliani, Roberto; Schwartz, Ida Vanessa D.; Guffon, Nathalie; Teles, Elisa Leao; Miranda, M. Clara Sa; Wraith, J. Edmond; Beck, Michael; Arash, Laila; Scarpa, Maurizio; Ketteridge, David; Hopwood, John J.; Plecko, Barbara; Steiner, Robert; Whitley, Chester B.; Kaplan, Paige; Yu, Zi-Fan; Swiedler, Stuart J.; Decker, Celeste. MOL GENET METAB. 2008. ; 94(4):469-475 IF: 2.629 <a href="#">Riferimento WoK</a> <a href="#">DOI</a></p>
55)	<p>Lysosomal storage diseases and the blood-brain barrier. Begley, David J.; Pontikis, Charles C.; Scarpa, Maurizio. Current Pharmaceutical Design. 2008. ; 14(16):1566-1580 IF: 4.399 <a href="#">Riferimento WoK</a></p>
56)	<p>Eighteen-year follow-up of the first Italian MPSI patient treated with bone marrow transplantation. Messina, C.; Rampazzo, A.; Cesaro, S.; Monciotti, C.; Gasparotto, N.; Tomanin, R.; Scarpa, M.. Bone Marrow Transplantation. 2008. ; 41(10):905-906 IF: 3.4 <a href="#">Riferimento WoK</a> <a href="#">DOI</a></p>
57)	<p>Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease. Di Natale, Paola; Villani, Guglielmo R. D.; Parini, Rossella; Scarpa, Maurizio; Parenti, Giancarlo; Pontarelli, Gianfranco; Grosso, Michela; Sersale, Giovanna; Tomanin, Rosella; Sibilio, Michelina; Barone, Rita; Fiumara, Agata. BIOTECHNOL APPL BIOC. 2008. ; 49(0):219-223 IF: 1.288 <a href="#">Riferimento WoK</a> <a href="#">DOI</a></p>
58)	<p>Seventh international symposium on lysosomal storage diseases. Aerts, Johannes; Beck, Michael; Martin, Rick; Scarpa, Maurizio. ACTA PAEDIATR. 2008. ; 97(0):1-2 IF: 1.517</p>

	<a href="#">Riferimento WoK DOI</a>
59)	Lysosomal storage diseases: new challenges. Scarpa, Maurizio; Eto, Yoshikatsu. ACTA PAEDIATR. 2008. ; 97(0):5-6 IF: 1.517 <a href="#">Riferimento WoK DOI</a>
60)	Mucopolysaccharidosis type II in a female patient: clinical presentation and follow-up examination after 6 months of enzyme replacement therapy. Rampazzo, A.; Cananzi, M.; Salviati, L.; Tomanin, R.; Gasparotto, N.; Drigo, P.; Scarpa, M.. ACTA PAEDIATR. 2008. ; 97(0):99-99 IF: 1.517 <a href="#">Riferimento WoK</a>
61)	Efficient transduction of human amniotic stem cells with an adenovirus-expressing iduronate-2-sulphatase: a potential approach for therapy of mucopolysaccharidosis type II?. Grisafi, D.; Friso, A.; Piccoli, M.; Pozzobon, M.; De Coppi, P.; Chiandetti, L.; Zaramellal, P.; Scarpa, M.; Tomanin, R.. ACTA PAEDIATR. 2008. ; 97(0):102-102 IF: 1.517 <a href="#">Riferimento WoK</a>
62)	Efficacy of adenovirus-mediated gene therapy in the mouse model of mucopolysaccharidosis type II. Tomanin, R.; Zaccariotto, E.; Marigo, I.; Friso, A.; Grisafi, D.; Bordin, M.; Salvalaio, M.; Scarpa, M.. ACTA PAEDIATR. 2008. ; 97(0):102-102 IF: 1.517 <a href="#">Riferimento WoK</a>
63)	Neurological manifestations of Hunter syndrome: new insights from HOS - the Hunter outcome survey. Scarpa, M.; Beck, M.; Wraith, J. E.. ACTA PAEDIATR. 2008. ; 97(0):103-104 IF: 1.517 <a href="#">Riferimento WoK</a>
64)	A rapid testing procedure for Fabry disease: alpha-galactosidase A assay in dried blood spots. Gasparotto, N.; Tomanin, R.; Frigo, A. C.; Pasquini, E.; Donati, A.; Niizawa, G.; Blanco, M.; Scarpa, M.. ACTA PAEDIATR. 2008. ; 97(0):112-112 IF: 1.517 <a href="#">Riferimento WoK</a>
65)	Neurological examinations and clinical manifestations in MPS I Registry patients. Scarpa, Maurizio. MOL GENET METAB. 2008. ; 93(2):81 - IF: 2.629 <a href="#">Riferimento WoK DOI</a>
66)	Brains for brain: A new Consortium for the research and the therapy of LSDs. Scarpa, Maurizio; Begley, David. MOL GENET METAB. 2008. ; 93(2):82 - IF: 2.629 <a href="#">Riferimento WoK DOI</a>
67)	In vivo evaluation of genistein for GAG storage reduction. Scarpa, Maurizio; Friso, Adelaide; Tomanin, Rosella; Salvalaio, Marika; Bordin, Mauro; Zacchello, Franco. MOL GENET METAB. 2008. ; 93(2):83 - IF: 2.629

	<a href="#">Riferimento WoK DOI</a>
68)	Neurological manifestations of hunter syndrome: Insights from HOS, the hunter outcome survey. Scarpa, Maurizio; Beck, Michael; Wraith, Edward J.. MOL GENET METAB. 2008. ; 93(2):84 - IF: 2.629 <a href="#">Riferimento WoK</a>
69)	A zebrafish iduronate-2-sulfatase candidate orthologue is strongly expressed during early embryonic development. Scarpa, Maurizio; Moro, Enrico; Tomanin, Rosella; Friso, Adelaide; Modena, Nicola; Bortolussi, Marino; Argenton, Francesco. MOL GENET METAB. 2008. ; 93(2):85 - IF: 2.629 <a href="#">Riferimento WoK</a>
70)	Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Wraith, J. Edmond; Scarpa, Maurizio; Beck, Michael; Bodamer, Olaf A.; De Meirleir, Linda; Guffon, Nathalie; Lund, Allan Meldgaard; Malm, Gunilla; Van der Ploeg, Ans T.; Zeman, Jiri. EUR J PEDIATR. 2008. ; 167(3):267-277 IF: 1.416 <a href="#">Riferimento WoK DOI</a>
71)	Multidisciplinary Management of Hunter Syndrome. Muenzer, Joseph; Beck, M.; Eng, C. M.; Escolar, M. L.; Giugliani, R.; Guffon, N. H.; Harmatz, P.; Kamin, W.; Kampmann, C.; Koseoglu, S. T.; Link, B.; Martin, R. A.; Molter, D. W.; Munoz Rojas, M. V.; Ogilvie, J. W.; Parini, R.; Ramaswami, U.; Scarpa, M.; Schwartz, I. V.; Wood, R. E.; Wraith, E.. Pediatrics. 2009. ; 124(6):E1228-E1239 IF: 4.789 <a href="#">Riferimento WoK DOI</a>
72)	Segregation analysis in a family at risk for the Maroteaux-Lamy syndrome conclusively reveals c.1151G > A (p.S384N) as to be a polymorphism. Zanetti, Alessandra; Ferraresi, Elena; Picci, Luigi; Filocamo, Mirella; Parini, Rossella; Rosano, Camillo; Tomanin, Rosella; Scarpa, Maurizio. European Journal of Human Genetics. 2009. ; 17(9):1160-1164 IF: 3.925 <a href="#">Riferimento WoK DOI</a>
73)	Mucopolysaccharidosis VI: the Italian experience. Scarpa, Maurizio; Barone, Rita; Fiumara, Agata; Astarita, Luca; Parenti, Giancarlo; Rampazzo, Angelica; Sala, Stefania; Sorge, Giovanni; Parini, Rossella. EUR J PEDIATR. 2009. ; 168(10):1203-1206 IF: 1.416 <a href="#">Riferimento WoK DOI</a>
74)	THE BURDEN OF SURGERY IN HUNTER SYNDROME: DATA FROM THE HUNTER OUTCOME SURVEY. Parini, R.; Furfan, F.; Wraith, J. E.; Scarpa, M.; Beck, M.; Muenzer, J.; Giugliani, R.. MOL GENET METAB. 2009. ; 98(1):440 - IF: 2.629 <a href="#">Riferimento WoK</a>
75)	Rapid diagnostic testing procedures for lysosomal storage disorders: alpha-glucosidase and beta-galactosidase assays on dried blood spots. Gasparotto, Nicoletta; Tomanin, Rosella; Frigo, Anna Chiara; Niizawa, Gabriela; Pasquini, Elisabetta; Blanco, Mariana; Donati, Maria Alice; Keutzer, Joan; Zacchello, Franco; Scarpa,

	<p>Maurizio.  Clinica Chimica Acta. 2009. ; 402(1):38-41 IF: 2.96  <a href="#">Riferimento WoK</a> <a href="#">DOI</a></p>
77)	<p>Novel therapies and future perspectives.  Scarpa, M.; Frustaci, A..  International Journal of Clinical Pharmacology and Therapeutics. 2009. ; 47(0):S109-S110 IF: 1.381  <a href="#">Riferimento WoK</a></p>
78)	<p>CNS imaging evaluation: toward the creation of a severity score.  Manara, R.; Mardari, R.; Rampazzo, A.; Scarpa, M..  International Journal of Clinical Pharmacology and Therapeutics. 2010. ; 48(0):S38-S39 IF: 1.381  <a href="#">Riferimento WoK</a></p>
79)	<p>Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II.  Friso, A.; Tomanin, R.; Salvalaio, M.; Scarpa, M..  British Journal of Pharmacology. 2010. ; 159(5):1082-1091 IF: 5.204  <a href="#">Riferimento WoK</a> <a href="#">DOI</a></p>
80)	<p>Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.  Harmatz, Paul; Yu, Zi-Fan; Giugliani, Roberto; Schwartz, Ida Vanessa D.; Guffon, Nathalie; Teles, Elisa Leao; Sa Miranda, M. Clara; Wraith, J. Edmond; Beck, Michael; Arash, Laila; Scarpa, Maurizio; Ketteridge, David; Hopwood, John J.; Plecko, Barbara; Steiner, Robert; Whitley, Chester B.; Kaplan, Paige; Swiedler, Stuart J.; Hardy, Karen; Berger, Kenneth I.; Decker, Celeste.  J INHERIT METAB DIS. 2010. ; 33(1):51-60 IF: 3.598  <a href="#">Riferimento WoK</a> <a href="#">DOI</a></p>
81)	<p>A novel functional role of iduronate-2-sulfatase in zebrafish early development.  Moro, Enrico; Tomanin, Rosella; Friso, Adelaide; Modena, Nicola; Tiso, Natascia; Scarpa, Maurizio; Argenton, Francesco.  Matrix Biology. 2010. ; 29(1):43-50 IF: 3.558  <a href="#">Riferimento WoK</a> <a href="#">DOI</a></p>
82)	<p>A 10-year large-scale cystic fibrosis carrier screening in the Italian population.  Picci, Luigi; Cameran, Marilena; Marangon, Oriana; Marzenta, Diana; Ferrari, Stefano; Frigo, Anna Chiara; Scarpa, Maurizio.  Journal of Cystic Fibrosis. 2010. ; 9(1):29-35 IF: 2.239  <a href="#">Riferimento WoK</a> <a href="#">DOI</a></p>
83)	<p>Pathophysiology of neuropathic lysosomal storage disorders.  Bellettato CM, Scarpa M. (2010)  J Inherit Metab Dis. 2010 Apr 29. [Epub ahead of print] IF: 3.598  <a href="#">PUBMED</a></p>
84)	<p>Diagnosis and Management of ophthalmologic features in patients with mucopolysaccharidosis</p>

	<p>Ferrari S., Ponzin D, Ashworth JL, Teär Fahnehjelm K., Summers CG. Harmatz P. and Scarpa M.  (2010) Brit. J. Ophtalmol. In press IF: 2.91</p>
85)	<p>Enzyme replacement therapy for Mucopolysaccharidosis VI: Groeth abd pubertal development In patients treated with recombinant N-Acetylgalactosamine 4-sulfatase  Decker C., Yu Z-F., Giugliani R., Schwartz IVD., Guffin N., Teles ES., Sa Miranda MC., Wraith JE., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood JJ., Plecko B., Steiner R., Whitley CB., Kaplan P., Swiedler SJ., Conrad S., and Harmatz P.. (2010). J. PEd. Rehabil. Med. 3, 2, 89-100.</p>
86)	<p>Evaluation of disease severity in mucopolysaccharidosis  Beck M., Muenzer J., and Scarpa M., (2010)  J. Pediat. Rehabil. Med. 3, 39-46</p>
87)	<p>Systemic therapies for mucopolysaccharidosis: ocular changes following haematopoietic stem cell transplantation or enzyme replacement therapy,  Gail Summers C., Teär Fahnehjelm K., Pitz S., Guffon N., Koseoglu ST., Harmatz P., Scarpa M.  (2010) Clin. Exp. Ophthalmol. (in press)</p>